EpiCept Corporation (Nasdaq OMX Stockholm Exchange and Nasdaq: EPCT) today announced that Nasdaq OMX Stockholm AB has approved the Company's request for a primary listing of its common stock on the Nasdaq OMX Stockholm Exchange. The Company previously had a secondary listing on Nasdaq OMX Stockholm. EpiCept sought the change in status in recognition of the Company's large Swedish shareholder base and the historical trading volume of the Company's common stock on the Exchange. The change in status became effective September 5, 2011 and does not affect the Company's short name and order book I.D. on the Exchange or the trading of its common stock on the Nasdaq Capital Market. The Company will continue to make quarterly and other regulatory filings with the Securities and Exchange Commission.
EpiCept President & CEO Jack Talley commented, "We are very pleased to be awarded a primary listing on the Nasdaq OMX Stockholm Exchange. This successful action confirms our desire to more broadly meet the needs of our shareholders in Sweden and in other countries that prefer to invest in EpiCept and trade our common stock on a liquid, high quality exchange outside the United States."